Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27512047 | 0.82 | ALDH1A1 (0.48) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL15831504 | 0.82 | MAPT (0.43) | MEN1KMT2AMAPTRAB9AKDM4E | |
| SCHEMBL4149136 | 0.80 | MAPK10 (0.49) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL7049484 | 0.80 | HAO1 (0.49) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL3957483 | 0.78 | NPSR1 (0.50) | MEN1KMT2AMAPTRAB9AMAPK1 | |
| SCHEMBL8842380 | 0.78 | ABCG2 (0.43) | MAPTKDM4ETSHRMAPK1HTR2B | |
| SCHEMBL11337052 | 0.76 | KMT2A (0.53) | MEN1KMT2ARAB9ATDP1KDM4E | |
| SCHEMBL10912483 | 0.74 | NPC1 (0.58) | MEN1KMT2ARAB9ALMNATSHR | |
| SCHEMBL27672131 | 0.73 | CA1 (0.56) | CDK2CDK1ROCK1 | |
| SCHEMBL4163888 | 0.73 | KMT2A (0.45) | MEN1KMT2AMAPTRAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | claimed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | claimed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| CN-116390760-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4188380-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2023-06-07 | — | — | EP | claimed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | claimed |
| WO-2023275649-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2023-01-05 | — | — | WO | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| CN-114938810-A | Thifluzamide and azoxystrobin-containing bactericidal composition suitable for unmanned aerial defense | 赤天化科技集团有限公司 | 2022-08-26 | — | — | CN | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | claimed |
| WO-2006099957-A1 | INSECTICIDAL AND ACARICIDAL ANILINOTRIAZOLES | BAYER CROPSCIENCE AG (DE) | 2006-09-28 | — | — | WO | claimed |
| EP-0073931-B1 | ANILINO-1,2,3-TRIAZOLE DERIVATIVES, MEDICAMENTS CONTAINING THEM, PROCESS FOR PREPARING THEM, AND THEIR USE | BOEHRINGER INGELHEIM KG (DE) | 1985-02-13 | — | — | EP | claimed |
| EP-4729067-A2 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS WITH A SHEET OF ANISOTROPIC MATERIAL | Novocure GmbH (CH) | 2026-04-22 | — | — | EP | disclosed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12415844-B2 | BCMA specific VCAR compositions and methods for use | POSEIDA THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12383738-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2025-08-12 | — | — | US | disclosed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | disclosed |
| US-20250025473-A1 | CELL IMPERMEABLE KINASE INHIBITORS TO TREAT SARS-COV-2 AND/OR HSV VIRAL INFECTIONS | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2025-01-23 | — | — | US | disclosed |
| US-20250001166-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-01-02 | — | — | US | disclosed |
| CN-119119296-A | Allogeneic cell compositions and methods of use | 波赛达治疗公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118878697-A | VCAR compositions and methods of use | 波赛达治疗公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | disclosed |
| CN-113383018-B | Allogeneic cell compositions and methods of use | 波赛达治疗公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4413038-A1 | PD-L1 BINDING AFFIMERS | Avacta Life Sciences Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| EP-4412711-A1 | SERUM HALF-LIFE EXTENDED PD-L1 BINDING POLYPEPTIDES | Avacta Life Sciences Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| CN-112218885-B | VCAR compositions and methods of use | 波赛达治疗公司 | 2024-06-18 | — | — | CN | disclosed |
| US-12005253-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2024-06-11 | — | — | US | disclosed |
| US-20240166759-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | ANGIEX, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | disclosed |
| EP-4344414-A1 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS (TTFIELDS) WITH A SHEET OF ANISOTROPIC MATERIAL | Novocure GmbH (CH) | 2024-04-03 | — | — | EP | disclosed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4313033-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313144-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117425476-A | Boric acid compounds, compositions and methods | 塔夫茨大学的受托人 | 2024-01-19 | — | — | CN | disclosed |
| CN-117355333-A | Combination comprising anti-TM 4SF1 antibody and immunotherapeutic agent and method of use thereof | 安吉克公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023218243-A1 | LAG-3/PD-L1 BINDING FUSION PROTEINS | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| EP-4262878-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| CN-116390760-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-4188380-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2023-06-07 | — | — | EP | disclosed |
| EP-4185586-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2023-05-31 | — | — | EP | disclosed |
| CN-116157398-A | 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy | 意大发马克股份公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023086547-A1 | CELL IMPERMEABLE KINASE INHIBITORS TO TREAT SARS-COV-2 AND/OR HSV VIRAL INFECTIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| CN-116133658-A | Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same | 株式会社 钟根堂 | 2023-05-16 | — | — | CN | disclosed |
| US-20230121433-A1 | CHIMERIC STIMULATORY RECEPTORS AND METHODS OF USE IN T CELL ACTIVATION AND DIFFERENTIATION | POSEIDA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023057946-A1 | SERUM HALF-LIFE EXTENDED PD-L1 BINDING POLYPEPTIDES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057567-A1 | PD-L1 BINDING AFFIMERS | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023012707-A1 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS (TTFIELDS) WITH A SHEET OF ANISOTROPIC MATERIAL | NOVOCURE GMBH (CH) | 2023-02-09 | — | — | WO | disclosed |
| US-20230037806-A1 | Electrode Assembly for Applying Tumor Treating Fields (TTFields) with a Sheet of Anisotropic Material | NOVOCURE GMBH (CH) | 2023-02-09 | — | — | US | disclosed |
| US-20230039099-A1 | AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-4126053-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115697413-A | Radiopharmaceuticals and imaging agents targeting FAP and uses related thereto | 塔夫茨大学信托人 | 2023-02-03 | — | — | CN | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4118107-A1 | CHIMERIC STIMULATORY RECEPTORS AND METHODS OF USE IN T CELL ACTIVATION AND DIFFERENTIATION | Poseida Therapeutics, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | disclosed |
| WO-2023275649-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2023-01-05 | — | — | WO | disclosed |
| US-20220395575-A1 | COMBINATION THERAPY WITH PROTEIN KINASE B ACTIVATION INHIBITOR TO TREAT CANCER | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220389077-A1 | ALLOGENEIC CELL COMPOSITIONS AND METHODS OF USE | POSEIDA THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220372491-A1 | TREATMENT OF RENAL CYSTIC DISEASE | MONASH UNIVERSITY (AU) | 2022-11-24 | — | — | US | disclosed |
| US-20220370647-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-11-24 | — | — | US | disclosed |
| WO-2022234003-A1 | CD33 BINDING POLYPEPTIDES WITH STEFIN A PROTEIN | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-115175686-A | AKT inhibitors for enhancing persistence of chimeric T cells | H·李·莫菲特癌症中心研究所公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022204368-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204565-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | ANGIEX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-4061383-A1 | AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-4051273-A1 | TREATMENT OF RENAL CYSTIC DISEASE | Monash University (AU) | 2022-09-07 | — | — | EP | disclosed |
| CN-114938810-A | Thifluzamide and azoxystrobin-containing bactericidal composition suitable for unmanned aerial defense | 赤天化科技集团有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220259673-A1 | METHODS FOR IDENTIFYING AND TREATING HIGH-PLASTICITY CELL STATE DRIVING TUMOR PROGRESSION IN LUNG CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-07-07 | — | — | US | disclosed |
| WO-2022133288-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | disclosed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | disclosed |
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021195198-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021188849-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021183474-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021183795-A1 | CHIMERIC STIMULATORY RECEPTORS AND METHODS OF USE IN T CELL ACTIVATION AND DIFFERENTIATION | POSEIDA THERAPEUTICS, INC. (US) | 2021-09-16 | — | — | WO | disclosed |
| CN-113383018-A | Allogeneic cell compositions and methods of use | 波赛达治疗公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3847197-A1 | ALLOGENEIC CELL COMPOSITIONS AND METHODS OF USE | Poseida Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210163599-A1 | PD-L1 BINDING AFFIMERS, AND USES RELATED THERETO | AVACTA LIFE SCIENCES LIMITED (GB) | 2021-06-03 | — | — | US | disclosed |
| WO-2021102038-A1 | AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021097401-A1 | COMBINATION THERAPY WITH PROTEIN KINASE B ACTIVATION INHIBITOR TO TREAT CANCER | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139557-A1 | VCAR COMPOSITIONS AND METHODS FOR USE | POSEIDA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| WO-2021081580-A1 | TREATMENT OF RENAL CYSTIC DISEASE | MONASH UNIVERSITY (AU) | 2021-05-06 | — | — | WO | disclosed |
| US-20210130845-A1 | COMPOSITIONS AND METHODS FOR CHIMERIC LIGAND RECEPTOR (CLR)-MEDIATED CONDITIONAL GENE EXPRESSION | POSEIDA THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021074695-A1 | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. | AVACTA LIFE SCIENCES LIMITED (GB) | 2021-04-22 | — | — | WO | disclosed |
| US-20210107993-A1 | CARTYRIN COMPOSITIONS AND METHODS FOR USE | POSEIDA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210102165-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | disclosed |
| CN-112601583-A | CARTyrin compositions and methods of use | 波赛达治疗公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3774868-A1 | PD-L1 BINDING AFFIMERS, AND USES RELATED THERETO | Avacta Life Sciences Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3762106-A1 | CARTYRIN COMPOSITIONS AND METHODS FOR USE | Poseida Therapeutics, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-112218885-A | VCAR compositions and methods of use | 波赛达治疗公司 | 2021-01-12 | — | — | CN | disclosed |
| WO-2019173636-A9 | CARTYRIN COMPOSITIONS AND METHODS FOR USE | POSEIDA THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| EP-3728305-A1 | VCAR COMPOSITIONS AND METHODS FOR USE | Poseida Therapeutics, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| CN-111727256-A | Compositions and methods for Chimeric Ligand Receptor (CLR) -mediated conditional gene expression | 波赛达治疗公司 | 2020-09-29 | — | — | CN | disclosed |
| EP-3679145-A2 | COMPOSITIONS AND METHODS FOR CHIMERIC LIGAND RECEPTOR (CLR)-MEDIATED CONDITIONAL GENE EXPRESSION | Poseida Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019197583-A1 | PD-L1 BINDING AFFIMERS, AND USES RELATED THERETO | AVACTA LIFE SCIENCES LIMITED (GB) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019173636-A1 | CARTYRIN COMPOSITIONS AND METHODS FOR USE | POSEIDA THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019104065-A1 | ANTI-AGING METHODS AND COMPOSITIONS | TURRINII PHARMACEUTICAL, LLC (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019051424-A2 | COMPOSITIONS AND METHODS FOR CHIMERIC LIGAND RECEPTOR (CLR)-MEDIATED CONDITIONAL GENE EXPRESSION | POSEIDA THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-2683714-B1 | II (PI)-CONJUGATED FLUOROIONOPHORES AND METHOD FOR DETERMINING AN ALKALI ION | UNIV POTSDAM (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-20180320133-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-08 | — | — | US | disclosed |
| EP-3370743-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | City of Hope (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2782922-B1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | BAYER IP GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017079528-A9 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017079528-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE (US) | 2017-05-11 | — | — | WO | disclosed |
| US-9593140-B2 | Antibacterial tylosin derivatives and methods for their preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-14 | — | — | US | disclosed |
| US-9499497-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150336903-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-26 | — | — | US | disclosed |
| US-9073875-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2855698-A2 | TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-104312003-A | High-resistance polypropylene sheet | Hefei daan printing co ltd | 2015-01-28 | — | — | CN | disclosed |
| CN-104302653-A | Antibacterial tylosin derivatives and methods for their preparation | BAYER IP GMBH | 2015-01-21 | — | — | CN | disclosed |
| US-20140349954-A1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | ELANCO ANIMAL HEALTH GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| EP-2010516-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-02 | — | — | EP | disclosed |
| CN-101472911-B | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA NV | 2014-07-02 | — | — | CN | disclosed |
| US-20140179699-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-26 | — | — | US | disclosed |
| CN-103666391-A | Composite antifreezing solution composition formula | QINGDAO CHENXUTONG COMMERCE & TRADE CO LTD | 2014-03-26 | — | — | CN | disclosed |
| US-20130344607-A1 | PI-CONJUGATED FLUOROIONOPHORES AND METHOD FOR DETERMINING AN ALKALI ION | UNIVERSITAET POTSDAM (DE) | 2013-12-26 | — | — | US | disclosed |
| WO-2013177426-A2 | TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| CN-103160255-A | Motor vehicle antifreeze fluid with good stability | QINGDAO WENSHENG AUTOMOBILE COMPONENTS & PARTS CO LTD | 2013-06-19 | — | — | CN | disclosed |
| CN-101489525-B | Use of aminophenylbenzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of UV radiation and cosmetic compositions thereof | CIBA HOLDING INC | 2013-06-19 | — | — | CN | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| EP-1981876-B1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| EP-2207770-A1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-1663211-B1 | AMINOTRIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| US-7598245-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| CN-101472911-A | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-01 | — | — | CN | disclosed |
| WO-2009071888-A1 | PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009060053-A1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| CN-101370802-A | Triazoloanilinopyrimidine derivatives for use as antiviral agents | ARROW THERAPEUTICS LTD (GB) | 2009-02-18 | — | — | CN | disclosed |
| EP-2010516-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-07 | — | — | EP | disclosed |
| EP-1981876-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007118903-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007080401-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| US-7226920-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| JP-2006265209-A | INSECTICIDAL ANILINOTRIAZOLE COMPOUNDS | BAYER CROPSCIENCE AG | 2006-10-05 | — | — | JP | disclosed |
| WO-2006099957-A1 | INSECTICIDAL AND ACARICIDAL ANILINOTRIAZOLES | BAYER CROPSCIENCE AG (DE) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006099957-A1 | INSECTICIDAL AND ACARICIDAL ANILINOTRIAZOLES | BAYER CROPSCIENCE AG (DE) | 2006-09-28 | — | — | WO | disclosed |
| US-20050261268-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-11-24 | — | — | US | disclosed |
| CN-1053660-C | Process for preparing indole derivatives containing 1,2,4-triazol-1-yl substituents | MERCK SHARP & DOHME (GB) | 2000-06-21 | — | — | CN | disclosed |
| CN-1037843-C | Process for preparing indole derivatives containing 1,2, 4-triazol-1-yl substituents | MERCK SHARP & DOHME (GB) | 1998-03-25 | — | — | CN | disclosed |
| US-5717104-A | Process for preparing indole derivatives containing a 1,2,4-triazol-1-yl substituent | MERCK, SHARP & DOHME, LTD. (GB) | 1998-02-10 | — | — | US | disclosed |
| CN-1166486-A | Process for preparing indole derivatives containing 1,2,4-triazol-1-yl substituents | MERCK SHARP & DOHME (GB) | 1997-12-03 | — | — | CN | disclosed |
| EP-0651748-B1 | PROCESS FOR PREPARING INDOLE DERIVATIVES CONTAINING A 1,2,4-TRIAZOL-1-YL SUBSTITUENT | MERCK SHARP & DOHME (GB) | 1997-10-08 | — | — | EP | disclosed |
| EP-0679647-B1 | Novel antifungal triazole compound and production and use thereof | NIHON NOHYAKU CO LTD (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5629332-A | FUNGICIDES | NIHON NOHYAKU CO., LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| US-5567819-A | Process for preparing indole derivatives containing a 1,2,4-triazol-1-yl substituent | MERCK, SHARP & DOHME, LTD. (GB) | 1996-10-22 | — | — | US | disclosed |
| EP-0679647-A1 | Novel antifungal triazole compound and production and use thereof | NIHON NOHYAKU CO., LTD. (JP) | 1995-11-02 | — | — | EP | disclosed |
| EP-0651748-A1 | PROCESS FOR PREPARING INDOLE DERIVATIVES CONTAINING A 1,2,4-TRIAZOL-1-YL SUBSTITUENT. | MERCK SHARP & DOHME (GB) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002476-A1 | PROCESS FOR PREPARING INDOLE DERIVATIVES CONTAINING A 1,2,4-TRIAZOL-1-YL SUBSTITUENT | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| US-4505912-A | SLEEP POTENTIATORS AND BLOOD CIRCULATION ENHANCERS | BOEHRINGER INGELHEIM KG (DE) | 1985-03-19 | — | — | US | disclosed |
| EP-0073931-B1 | ANILINO-1,2,3-TRIAZOLE DERIVATIVES, MEDICAMENTS CONTAINING THEM, PROCESS FOR PREPARING THEM, AND THEIR USE | BOEHRINGER INGELHEIM KG (DE) | 1985-02-13 | — | — | EP | disclosed |
| US-4492699-A | NERVOUS SYSTEM DISORDERS | LILLY INDUSTRIES LIMITED (GB) | 1985-01-08 | — | — | US | disclosed |
| EP-0040357-B1 | PROCESS FOR THE PREPARATION OF V-TRIAZOLYL-(2) PHENOLS | BAYER AG (DE) | 1984-09-19 | — | — | EP | disclosed |
| US-4431589-A | NEUROLEPTIC AGENTS; TRANQUILIZERS; CENTRAL NERVOUS SYSTEM DISORDERS | Lilly House (GB) | 1984-02-14 | — | — | US | disclosed |
| EP-0073931-A1 | Anilino-1,2,3-triazole derivatives, medicaments containing them, process for preparing them, and their use | BOEHRINGER INGELHEIM KG (DE) | 1983-03-16 | — | — | EP | disclosed |
| EP-0073931-A1 | Anilino-1,2,3-triazole derivatives, medicaments containing them, process for preparing them, and their use | BOEHRINGER INGELHEIM KG (DE) | 1983-03-16 | — | — | EP | disclosed |
| EP-0054416-A2 | Benzodiazepine compounds and their use as pharmaceuticals | Lilly Industries Limited (GB) | 1982-06-23 | — | — | EP | disclosed |
| EP-0040357-A1 | Process for the preparation of v-triazolyl-(2) phenols | BAYER AG (DE) | 1981-11-25 | — | — | EP | disclosed |
| EP-0040357-A1 | Process for the preparation of v-triazolyl-(2) phenols | BAYER AG (DE) | 1981-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (22 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | MMP1, MMP8, CCL11 | MEN1 4853/4885KMT2A 4026/4885MAPT 3332/4885 |
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | SLC28A1, TPMT, ACE | MEN1 4286/4885KMT2A 3712/4885MAPT 2681/4885 |
| US-20180320133-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | MEN1 3640/4885KMT2A 1396/4885MAPT 2971/4885 |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | MEN1 1985/4885KMT2A 4040/4885MAPT 1967/4885 |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | MEN1 3640/4885KMT2A 1396/4885MAPT 2971/4885 |
| US-20220370647-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | MEN1 1985/4885KMT2A 4040/4885MAPT 1967/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | MEN1 1985/4885KMT2A 4040/4885MAPT 1967/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | MEN1 1645/4885KMT2A 2872/4885MAPT 1987/4885 |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP3K1 | MEN1 2530/4885KMT2A 508/4885MAPT 599/4885 |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | FAP, FIBP, FGFR1 | MEN1 3078/4885KMT2A 3435/4885MAPT 3059/4885 |
| US-20140349954-A1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | MLN, TMSB10, TMSB4X | MEN1 3664/4885KMT2A 3403/4885MAPT 2502/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | MEN1 4832/4885KMT2A 577/4885MAPT 4173/4885 |
| US-20150336903-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | MEN1 954/4885KMT2A 518/4885MAPT 2788/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | MEN1 1461/4885KMT2A 2966/4885MAPT 955/4885 |
| US-20130344607-A1 | PI-CONJUGATED FLUOROIONOPHORES AND METHOD FOR DETERMINING AN ALKALI ION | SLCO2A1, SLCO2B1, SLCO4C1 | MEN1 1475/4885KMT2A 1767/4885MAPT 3263/4885 |
| US-20250025473-A1 | CELL IMPERMEABLE KINASE INHIBITORS TO TREAT SARS-COV-2 AND/OR HSV VIRAL INFECTIONS | PDPK1, DAPK1, DAPK2 | MEN1 2932/4885KMT2A 2700/4885MAPT 900/4885 |
| US-20050261268-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP3K1 | MEN1 2530/4885KMT2A 508/4885MAPT 599/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | MEN1 180/4885KMT2A 1084/4885MAPT 1308/4885 |
| US-20140179699-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | MEN1 954/4885KMT2A 518/4885MAPT 2788/4885 |
| US-20210102165-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | MEN1 3640/4885KMT2A 1396/4885MAPT 2971/4885 |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | MEN1 4501/4885KMT2A 1945/4885MAPT 1731/4885 |
| US-20210163599-A1 | PD-L1 BINDING AFFIMERS, AND USES RELATED THERETO | PDCD1LG2, CD274, PDCD1 | MEN1 3444/4885KMT2A 2041/4885MAPT 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.